loading page

National Perinatal Association Guidance for Palivizumab Prophylaxis Increases Coverage to that Provided by the FDA Indication
  • Mitchell Goldstein,
  • Benjamin Harding,
  • Elba Fayard
Mitchell Goldstein
Loma Linda University School of Medicine
Author Profile
Benjamin Harding
Loma Linda University School of Medicine
Author Profile
Elba Fayard
Loma Linda University School of Medicine
Author Profile

Abstract

This editorial is an invited response to “Adherence to the 2014 American Academy of Pediatrics Palivizumab Prophylaxis Recommendations”

Peer review status:IN REVISION

12 Jan 2021Submitted to Pediatric Pulmonology
13 Jan 2021Submission Checks Completed
13 Jan 2021Assigned to Editor
24 Jan 2021Reviewer(s) Assigned
11 Feb 2021Review(s) Completed, Editorial Evaluation Pending
15 Feb 2021Editorial Decision: Revise Major
31 May 20211st Revision Received
31 May 2021Submission Checks Completed
31 May 2021Assigned to Editor
31 May 2021Reviewer(s) Assigned
31 May 2021Review(s) Completed, Editorial Evaluation Pending
02 Jun 2021Editorial Decision: Revise Minor